[go: up one dir, main page]

DK0720599T3 - Som hypocholesterolæmiske midler anvendelige hydroxysubstituerede azetidinoner - Google Patents

Som hypocholesterolæmiske midler anvendelige hydroxysubstituerede azetidinoner

Info

Publication number
DK0720599T3
DK0720599T3 DK94928563T DK94928563T DK0720599T3 DK 0720599 T3 DK0720599 T3 DK 0720599T3 DK 94928563 T DK94928563 T DK 94928563T DK 94928563 T DK94928563 T DK 94928563T DK 0720599 T3 DK0720599 T3 DK 0720599T3
Authority
DK
Denmark
Prior art keywords
aryl
alkyl
substd
hydroxy
coor6
Prior art date
Application number
DK94928563T
Other languages
Danish (da)
English (en)
Inventor
Stuart B Rosenblum
Sundeep Dugar
Duane A Burnett
John W Clader
Brian A Mckittrick
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26799377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0720599(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK0720599T3 publication Critical patent/DK0720599T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Dental Preparations (AREA)
  • Pyrrole Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK94928563T 1993-09-21 1994-09-14 Som hypocholesterolæmiske midler anvendelige hydroxysubstituerede azetidinoner DK0720599T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10244093A 1993-09-21 1993-09-21
US08/257,593 US5631365A (en) 1993-09-21 1994-06-09 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
PCT/US1994/010099 WO1995008532A1 (en) 1993-09-21 1994-09-14 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Publications (1)

Publication Number Publication Date
DK0720599T3 true DK0720599T3 (da) 1999-11-08

Family

ID=26799377

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94928563T DK0720599T3 (da) 1993-09-21 1994-09-14 Som hypocholesterolæmiske midler anvendelige hydroxysubstituerede azetidinoner

Country Status (35)

Country Link
US (5) US5631365A (de)
EP (1) EP0720599B1 (de)
JP (1) JP2803908B2 (de)
KR (1) KR100186853B1 (de)
CN (1) CN1050830C (de)
AT (1) ATE180249T1 (de)
AU (1) AU681445C (de)
BE (1) BE2014C056I2 (de)
BR (1) BR1100159A (de)
CA (1) CA2172149C (de)
CZ (2) CZ288861B6 (de)
DE (3) DE10399001I2 (de)
DK (1) DK0720599T3 (de)
ES (1) ES2132432T3 (de)
FI (1) FI110321B (de)
FR (2) FR05C0040I2 (de)
GE (1) GEP20043149B (de)
GR (1) GR3030312T3 (de)
HU (1) HU221185B1 (de)
IL (1) IL110956A (de)
LU (4) LU91050I2 (de)
MA (1) MA23332A1 (de)
MY (1) MY111314A (de)
NL (2) NL300132I2 (de)
NO (6) NO305902B1 (de)
NZ (1) NZ274041A (de)
PL (1) PL182617B1 (de)
RU (1) RU2138480C1 (de)
SG (1) SG46208A1 (de)
SK (1) SK281067B6 (de)
TN (1) TNSN94094A1 (de)
TW (1) TW427974B (de)
UA (1) UA41948C2 (de)
WO (1) WO1995008532A1 (de)
ZA (1) ZA947086B (de)

Families Citing this family (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1995035277A1 (en) * 1994-06-20 1995-12-28 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
DK0862645T3 (da) * 1995-09-27 2003-04-07 Schering Corp Stereoselektiv mikrobiel reduktionsproces
US5843938A (en) * 1995-10-03 1998-12-01 Beiersdorf-Lilly Gmbh Treatment of atherosclerosis
EP0766962A3 (de) * 1995-10-03 2000-05-10 Beiersdorf-Lilly GmbH Behandlung der Atherosclerose
CA2235943C (en) * 1995-10-31 2002-10-01 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AU7472896A (en) * 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
DK0939632T3 (da) 1996-02-23 2006-01-30 Lilly Co Eli Non-peptidyl vasopressin V1a antagonister
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
FR2762336B1 (fr) * 1997-04-21 1999-06-11 Francois Trantoul Procede de fabrication d'un film a motif non reproductible par lecture optique pour la protection de documents
US6133001A (en) * 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) * 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
WO2000034240A1 (en) * 1998-12-07 2000-06-15 Schering Corporation Process for the synthesis of azetidinones
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
ES2200588T3 (es) 1998-12-23 2004-03-01 G.D. Searle Llc Combinacion de inhibidores del transporte de oxido biliar ileal y de derivados de acido fibrico para indicaciones cardiovasculares.
NZ512534A (en) * 1998-12-23 2003-11-28 G Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
EP1140185B1 (de) 1998-12-23 2003-06-04 G.D. Searle LLC. Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
PT1140184E (pt) 1998-12-23 2003-10-31 Searle Llc Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com derivados de acido nicotinico para indicacoes cardiovasculares
DK1140190T3 (da) * 1998-12-23 2002-12-23 Searle Llc Kombinationer af ileumgaldesyretransport-inhibitorer og galdesyre-sekvestreringsmidler til cardiovaskulære indikatorer
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
EP1354604A1 (de) * 1998-12-23 2003-10-22 G.D. Searle LLC. Kombinationen für kardiovaskuläre Indikationen
PL348508A1 (en) 1998-12-23 2002-05-20 Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
WO2000060107A1 (en) 1999-04-05 2000-10-12 Schering Corporation Stereoselective microbial reduction for the preparation of 1 - (4-fluorophenyl) - 3(r)-[3(s) - hydroxy-3 - (4-fluorophenyl) propyl)]-4(s) - (4-hydroxyphenyl)-2-azetidinone
US6297268B1 (en) 1999-11-30 2001-10-02 Schering Corporation Imidazoles as cholesterol lowering agents
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
WO2001068637A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
WO2002036124A2 (en) * 2000-10-30 2002-05-10 Schering Corporation Treatment and method using loratadine and montelukast
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
IL155771A0 (en) * 2000-12-20 2003-12-23 Schering Corp Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1593670B1 (de) * 2000-12-20 2007-08-08 Schering Corporation Hydroxysubstituierte 2-Azetidinone verwendbar als Hypocholesterolemische Arzneimittel
EP1510521A1 (de) * 2000-12-20 2005-03-02 Schering Corporation Zuckersubstituierte 2-Azetidinone Verwendbar als Hypocholesterdenische Arzneimittel
AU1609702A (en) * 2000-12-21 2002-07-01 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
DE10064402A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10064398A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Neue Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
ES2287250T3 (es) * 2001-01-26 2007-12-16 Schering Corporation Combinaciones de secuestrante(s) de acidos biliares e inhibidor(es) de la absorcion de esteroles y tratamientos para indicaciones vasculares.
JP2004517916A (ja) * 2001-01-26 2004-06-17 シェーリング　コーポレイション ニコチン酸およびその誘導体ならびにステロール吸収阻害剤の併用、および血管適応症の治療
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
AU2007201970B2 (en) * 2001-01-26 2008-04-17 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
KR20080067717A (ko) * 2001-01-26 2008-07-21 쉐링 코포레이션 스테롤 흡수 억제제와 혈액 조절제를 포함하는 혈관 질환의치료 또는 예방용 약제학적 조성물
AU2008201609B8 (en) * 2001-01-26 2009-01-08 Organon Llc Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2006202618B2 (en) * 2001-01-26 2007-04-19 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ME00145B (me) * 2001-01-26 2010-10-10 Merck Sharp & Dohme Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
AU2006203175B2 (en) * 2001-01-26 2008-07-24 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
EP1911462A3 (de) 2001-01-26 2011-11-30 Schering Corporation Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
JP2004517919A (ja) * 2001-01-26 2004-06-17 シェーリング　コーポレイション 血管状態の処置のための心臓血管薬剤とステロール吸収インヒビターとの組み合わせ
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
WO2002079174A2 (en) 2001-03-28 2002-10-10 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
PT1392287E (pt) * 2001-05-25 2007-02-28 Schering Corp Métodos para tratamento de doença de alzheimer e/ou regulação dos níveis de peptídeos β amilóide num sujeito
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ES2272776T3 (es) 2001-09-21 2007-05-01 Schering Corporation Tratamiento de xantomas con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1859796A3 (de) * 2001-09-21 2008-07-02 Schering Corporation Behandlung von xanthom mit azetidinon-derivaten als hemmer der sterol absorption
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US6740663B2 (en) * 2001-11-02 2004-05-25 G.D. Searle, Llc Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
CA2466081A1 (en) * 2001-11-09 2003-05-15 Atherogenics, Inc. Methods of reversing and preventing cardiovascular pathologies
WO2003053368A2 (en) * 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
US7202247B2 (en) 2001-12-19 2007-04-10 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
WO2003074101A1 (en) * 2002-02-28 2003-09-12 Eli Lilly And Company Method of treating atherosclerosis and hypercholesterolemia
US20040116510A1 (en) * 2002-03-05 2004-06-17 Nichtberger Steven A. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
DE10227506A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227507A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
EP1656368A4 (de) 2002-07-09 2009-08-26 Bristol Myers Squibb Co Als antidiabetika und mittel gegen obesitas geeignete substituierte heterocyclische derivate und verfahren
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
CA2493614C (en) * 2002-07-30 2011-09-13 Karykion Inc. Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US20040181075A1 (en) * 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
CN1805926A (zh) * 2003-05-05 2006-07-19 兰贝克赛实验室有限公司 二苯基氮杂环丁酮衍生物的反式异构体的制备方法
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
OA13174A (en) * 2003-05-30 2006-12-13 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors.
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
CN1829519A (zh) * 2003-07-24 2006-09-06 默克公司 二苯基取代的环烷烃类,含有它们的组合物和应用的方法
AU2003259547A1 (en) * 2003-07-31 2005-02-14 Hetero Drugs Limited Ezetimibe polymorphs
EP1522541A1 (de) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Neue hypocholesterolemische Verbindungen
WO2005042692A2 (en) * 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
EP1680189A2 (de) * 2003-11-05 2006-07-19 Schering Corporation Kombinationen von lipidmodulierenden mitteln mit substituierten azetidinonen zur behandlung von vaskularen erkrankungen
EP1918000A2 (de) 2003-11-05 2008-05-07 Schering Corporation Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände
KR20070050861A (ko) * 2003-11-10 2007-05-16 마이크로비아 인코포레이티드 ４-비아릴일-１-페닐아제티딘-２-온
US7067675B2 (en) * 2003-11-24 2006-06-27 Hetero Drugs Limited Process for ezetimibe intermediate
BRPI0418004A (pt) * 2003-12-23 2007-04-17 Astrazeneca Ab composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, métodos para tratar ou prevenir condições hiperlipidêmicas, aterosclerose, mal de alzheimer, e tumores associados com colesterol, formulação farmacêutica, combinação, e, processo para preparar um composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
WO2005062824A2 (en) 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds
US7901893B2 (en) * 2004-01-16 2011-03-08 Merck Sharp & Dohme Corp. NPC1L1 (NPC3) and methods of identifying ligands thereof
US7932268B2 (en) 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
PL1756049T3 (pl) * 2004-05-21 2008-02-29 Sanofi Aventis Deutschland Sposób wytwarzania pochodnych 1,4-difenyloazetydynonu
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006004903A2 (en) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
WO2006026273A2 (en) * 2004-08-25 2006-03-09 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
AR050631A1 (es) * 2004-09-09 2006-11-08 Novartis Ag Combinacion de compuestos organicos
CA2581596A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
CA2592350A1 (en) * 2004-12-15 2006-06-22 Schering Corporation Functional assays for cholesterol absorption inhibitors
US20130082232A1 (en) 2011-09-30 2013-04-04 Unity Semiconductor Corporation Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells
US8361999B2 (en) 2005-04-04 2013-01-29 Pontificia Universidad Catolica De Chile Methods of treating cholesterol gallstone disease with ezetimibe
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
MX2007014162A (es) * 2005-05-09 2008-04-04 Microbia Inc Agentes de acoplamiento de bencenfosfonatos organometalicos.
EP1885703A4 (de) * 2005-05-11 2009-09-02 Microbia Inc Verfahren zur herstellung phenolischer 4-biphenylylazetidin-2-one
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2006127893A2 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
CN101198338A (zh) * 2005-06-15 2008-06-11 默克公司 抗高胆固醇血化合物
US7635705B2 (en) * 2005-06-20 2009-12-22 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
MY148538A (en) * 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US8013150B2 (en) * 2005-06-22 2011-09-06 Msn Laboratories Ltd. Process for the preparation of ezetimibe
EP1741427A1 (de) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmazeutische Zusammensetzung enthaltend Simvastatin und Ezetimibe
US20070049748A1 (en) * 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
EP1922304A2 (de) 2005-09-08 2008-05-21 Teva Pharmaceutical Industries Ltd Verfahren zur herstellung von (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinon, einem zwischenprodukt zur synthese von ezetimib
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2007054896A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
HU0501164D0 (en) * 2005-12-20 2006-02-28 Richter Gedeon Vegyeszet New industrial process for the production of ezetimibe
US20070161578A1 (en) * 2005-12-21 2007-07-12 Hwa Joyce J Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
EP1971573B1 (de) * 2005-12-22 2009-10-14 Medichem S.A. Verfahren zur herstellung von zwischenprodukten für die herstellung von ezetimibe
PE20071320A1 (es) 2006-01-18 2007-12-29 Schering Corp Moduladores de receptores cannabinoides
JP5001252B2 (ja) * 2006-02-16 2012-08-15 壽製薬株式会社 光学活性アルコールを製造する方法
EP1986489A2 (de) * 2006-02-24 2008-11-05 Schering Corporation Npc1l1-orthologe
CA2644905A1 (en) * 2006-03-06 2007-09-13 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
WO2007120824A2 (en) * 2006-04-10 2007-10-25 Teva Pharmaceutical Industries Ltd. Processes for the synthesis of azetidinone
TW200811098A (en) * 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
EP1937636A1 (de) * 2006-08-29 2008-07-02 Teva Pharmaceutical Industries Ltd. Verfahren zur reinigung von (3r,4s)-4-(4-hydroxy-protected-phenyl)-1-(4-fluorophenyl)-3-(4-fluorophenyl)-3-oxopropyl-azetidin-2-on
JP2010502702A (ja) * 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
CA2663502A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
WO2008033431A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
MX2009002918A (es) * 2006-09-15 2009-03-31 Schering Corp Derivados azetidinona y sus metodos de uso.
WO2008033468A2 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
WO2008033456A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
CN100564357C (zh) * 2006-10-20 2009-12-02 浙江天宇药业有限公司 一种氮杂环丁酮衍生物及其合成方法
EP2124549A4 (de) * 2006-12-20 2010-01-20 Merck & Co Inc Antihypercholesterinämische verbindungen
EP1939174A1 (de) * 2006-12-21 2008-07-02 LEK Pharmaceuticals D.D. Einschlusskomplex von Ezetimib und einem Cyclodextrin und Verfahren zu seiner Herstellung
AU2007338625A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
CN101679236B (zh) * 2007-01-24 2013-03-06 克尔克公司 依泽替米贝的制备方法和其的衍生物
WO2008096372A2 (en) * 2007-02-06 2008-08-14 Ind-Swift Laboratories Limited Process for preparing highly pure ezetimibe using novel intermediates
WO2008104875A1 (en) * 2007-03-01 2008-09-04 Pfizer Products Inc. Oxazolidinones as cholesterol absorption inhibitors
EP2133347A4 (de) 2007-03-06 2010-03-17 Teijin Pharma Ltd 1-biarylazetidinonderivate
EP2134169A2 (de) 2007-03-09 2009-12-23 Indigene Pharmaceuticals Inc. Kombination von metformid-r-(+)-lipoat und antihyperlipidämika für die behandlung von diabetes-hyperglykämie und diabetesbedingte komplikationen
WO2008123953A1 (en) * 2007-04-02 2008-10-16 Merck & Co., Inc. Anti-hypercholesterolemic compound
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
JP2010529148A (ja) * 2007-06-07 2010-08-26 テバ ファーマシューティカル インダストリーズ リミティド エゼチミブ製造のための還元方法
US20080318920A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched ezetimibe
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
CN101796033A (zh) * 2007-06-28 2010-08-04 英特维特国际股份有限公司 作为cb1拮抗剂的取代的哌嗪
JP2010531874A (ja) * 2007-06-28 2010-09-30 インターベット インターナショナル ベー． フェー． Ｃｂ１アンタゴニストとしての置換ピペラジン
CA2694378A1 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
US20090093627A1 (en) * 2007-08-30 2009-04-09 Lorand Szabo Process for preparing intermediates of ezetimibe by microbial reduction
WO2009027785A2 (en) * 2007-08-30 2009-03-05 Pfizer Products Inc. 1, 3-oxazole derivatives as cetp inhibitors
DE102007054497B3 (de) * 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
UA103179C2 (ru) 2007-12-10 2013-09-25 Ратиофарм Гмбх Фармацевтическая композиция, которая содержит эзетимиб
CZ305066B6 (cs) * 2008-02-25 2015-04-22 Zentiva, K.S. Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
EP2128133A1 (de) 2008-05-26 2009-12-02 Lek Pharmaceuticals D.D. Ezetiminverfahren und -zusammensetzung
CA2724873A1 (en) * 2008-06-06 2009-12-10 Nicox S.A. Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
CN102186972B (zh) 2008-08-29 2014-08-20 科德克希思公司 用于立体选择性生产(4s)-3-[(5s)-5-(4-氟苯基)-5-羟基戊酰基]-4-苯基-1，3-噁唑烷-2-酮的酮还原酶多肽
JP2012508791A (ja) 2008-11-14 2012-04-12 フラムローゼ，ボミ，ピー． アテローム性動脈硬化症の治療のための循環酸化低密度リポタンパク質‐ベータ‐２‐糖タンパク質１複合体を減少させる方法
EP2204170A1 (de) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmazeutische Zusammensetzung mit Ezetimibe und Simvastatin
EP2379562A1 (de) 2008-12-16 2011-10-26 Schering Corporation Bicyclische pyranonderivate als agonisten am nicotinsäurerezeptor
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2216016A1 (de) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die Ezetimib umfasst
EP2403848A1 (de) 2009-03-06 2012-01-11 Lipideon Biotechnology AG Pharmazeutische hypocholesterinemische zusammensetzungen
PL2229938T3 (pl) 2009-03-13 2012-09-28 Sanovel Ilac Sanayi Ve Ticaret As Kompozycje ezetymibu
EP2414326B1 (de) 2009-03-31 2017-12-20 Lupin Limited Zwischenprodukte für die herstellung von 1,4-diphenylazetidinon
EP2414529A2 (de) 2009-04-01 2012-02-08 Matrix Laboratories Ltd Enzymatisches verfahren zur herstellung von (s)-5-(4-fluorphenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-on, einer zwischenstufe von ezetimib, und weitere umwandlung zu ezetimib
WO2011002424A2 (en) 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
EP2448564A2 (de) 2009-07-02 2012-05-09 Bilgic Mahmut Löslichkeitsverstärkende pharmazeutische formulierung
WO2011019326A2 (en) 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
ES2575560T3 (es) 2009-08-19 2016-06-29 Codexis, Inc. Polipéptidos cetorreductasa para preparar fenilefrina
US9181364B2 (en) 2010-02-24 2015-11-10 Relypsa, Inc. Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants
KR101822608B1 (ko) 2010-02-24 2018-01-29 리립사, 인크. 담즙산 격리제로서 사용하기 위한 아민 폴리머
GB2490853B (en) 2010-02-24 2018-08-08 Relypsa Inc Polyimidazoles for use as bile acid sequestrants
EP2368543A1 (de) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Verfahren zur Herstellung einer granulierten pharmazeutischen Zusammensetzung mit Simvastatin und/oder Ezetimibe
DK2561069T3 (en) 2010-04-23 2017-05-01 Alexion Pharma Inc Enzyme for lysosomal storage disease
EP2566497B1 (de) 2010-05-04 2015-07-29 Codexis, Inc. Biokatalysatoren zur ezetimib-synthese
ES2372460B1 (es) 2010-07-09 2012-11-16 Moehs Ibérica S.L. Nuevo método para la preparación de ezetimiba.
RS53947B1 (sr) 2010-09-09 2015-08-31 Synageva Biopharma Corp. Primena lizozomalne kisele lipaze za lečenje nedostatka lizozomalne kisele lipaze kod pacijenata
SI3023102T1 (sl) 2010-11-04 2018-11-30 Albireo Ab IBAT inhibitorji za zdravljenje jetrnih bolezni
CN103228270B (zh) 2010-11-08 2016-02-10 阿尔比里奥公司 含ibat抑制剂和胆汁酸结合剂的药物组合
WO2012076030A1 (en) 2010-12-10 2012-06-14 Pharmathen S.A. Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
US8455474B2 (en) 2011-03-04 2013-06-04 Mackay Memorial Hospital Method for treating tuberculosis
WO2012155932A1 (en) 2011-05-17 2012-11-22 Pharmathen S.A. Improved process for the preparation of ezetimibe
PL231215B1 (pl) 2011-06-15 2019-02-28 Inst Chemii Organicznej Polskiej Akademii Nauk Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy
CN102675177A (zh) * 2011-06-28 2012-09-19 常州制药厂有限公司 一种降血脂药物及其关键中间体的制备方法
CN102952055A (zh) * 2011-08-16 2013-03-06 凯瑞斯德生化(苏州)有限公司 一种依泽替米贝和其中间体的制备方法
CN103204795B (zh) * 2012-01-11 2016-12-14 重庆华邦胜凯制药有限公司 一种手性氮杂环丁酮类化合物的制备方法
HUE052300T2 (hu) 2012-05-01 2021-04-28 Althera Life Sciences Llc Orális tablettakészítmény, amely a rozuvastatin és az ezetimib rögzített kombinációjából áll, hiperlipidémia és kardiovaszkuláris betegségek kezelésére
CN103570574B (zh) 2012-07-20 2016-04-13 中国科学院上海有机化学研究所 一种依泽替米贝的合成方法及该方法中所用的中间体
CN103102297A (zh) * 2012-09-28 2013-05-15 北京赛林泰医药技术有限公司 一种新的依折麦布的合成方法
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
CN103864708A (zh) * 2012-12-12 2014-06-18 天津市医药集团技术发展有限公司 一种依折麦布中间体的制备方法
WO2015039675A1 (en) 2013-09-23 2015-03-26 Pharmathen S.A. Novel process for the preparation of ezetimibe intermediates
EP3065736B1 (de) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon-rezeptor-antagonist-verbindungen, zusammensetzungen daraus und verfahren zur verwendung
US9926269B2 (en) 2013-12-18 2018-03-27 Rudjer Boskovic Institute Beta-lactam cholesterol absorption inhibitors
CN103739537B (zh) * 2013-12-24 2015-05-20 连云港恒运医药科技有限公司 依折麦布的新合成方法
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN103755616A (zh) * 2013-12-31 2014-04-30 北京万全德众医药生物技术有限公司 一种制备依泽替米贝异构体的方法
BR112016027778A2 (pt) 2014-05-30 2017-08-15 Pfizer Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
CN105294426B (zh) * 2014-06-09 2019-05-14 浙江海正药业股份有限公司 氮杂环丁酮化合物制备方法及其中间体
CN104447474A (zh) * 2014-11-11 2015-03-25 武汉武药科技有限公司 一种依折麦布异构体的合成方法
CN104387308A (zh) * 2014-11-18 2015-03-04 武汉福星生物药业有限公司 一种控制EZ-zanOH杂质产生制备高纯度依折麦布的方法
CN104513187B (zh) * 2015-01-09 2017-05-31 安润医药科技（苏州）有限公司 依折麦布及其中间体的合成方法
JP2016145173A (ja) * 2015-02-09 2016-08-12 株式会社トクヤマ （３ｒ，４ｓ）‐１‐（４‐フルオロフェニル）‐［３（ｓ）‐ヒドロキシ‐３‐（４‐フルオロフェニル）プロピル］‐（４‐ヒドロキシフェニル）‐２‐アゼチジノンの製造方法
WO2016149191A1 (en) 2015-03-13 2016-09-22 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN105287513A (zh) * 2015-10-23 2016-02-03 浙江永宁药业股份有限公司 一种依折麦布药物组合物及其制备方法
CN107098841A (zh) * 2016-02-19 2017-08-29 常州方楠医药技术有限公司 一种依折麦布的制备方法及该方法中所用的中间体
WO2018103642A1 (en) 2016-12-05 2018-06-14 Patsnap Systems, apparatuses, and methods for searching and displaying information available in large databases according to the similarity of chemical structures discussed in them
US20180338922A1 (en) 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
EP3437636A1 (de) 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmazeutische zusammensetzung mit ezetimibe
US11408274B2 (en) 2018-01-16 2022-08-09 Q.E.D. Environmental Systems, Inc. Fluid level monitoring system and method incorporating pressure sensor system having inflatable/collapsible bag
EP3942047A1 (de) 2019-03-20 2022-01-26 Regeneron Pharmaceuticals, Inc. Behandlung von erhöhten lipidspiegeln mit sterol-regulator-bindenden protein bindenden protein (scap) inhibitoren
CN116889627A (zh) 2019-03-20 2023-10-17 雷杰纳荣制药公司 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
WO2021019499A1 (en) 2019-07-31 2021-02-04 TECNIMEDE - Sociedade Técnico-medicinal, SA Solid oral multiple-unit immediate release compositions, methods and uses thereof
EP4188338A1 (de) 2020-07-27 2023-06-07 KRKA, d.d., Novo mesto Zweischichtige tablette mit ezetimib und atorvastatin
BR112023000808A2 (pt) 2020-07-29 2023-02-07 Amryt Pharmaceuticals Inc Lomitapida para uso em métodos para tratar hiperlipidemia e hipercolesterolemia em pacientes pediátricos
AU2022291920B2 (en) * 2021-06-17 2024-12-12 Zhejiang Hisun Pharmaceutical Co., Ltd. Hybutimibe intermediate and preparation method therefor
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
WO2024151311A1 (en) 2023-01-09 2024-07-18 Esperion Therapeutics, Inc. Methods of treatment using bempedoic acid
WO2025049568A1 (en) 2023-08-29 2025-03-06 Regeneron Pharmaceuticals, Inc. Treatment of muscle disorder with folliculin interacting protein 1 (fnip1) inhibitors and/or folliculin (flcn) inhibitors
EP4566591B1 (de) 2023-12-07 2025-12-31 KRKA, d.d., Novo mesto Feste pharmazeutische darreichungsform mit ezetimibe und pitavastatin

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2046823A1 (de) 1970-09-23 1972-03-30 Farbwerke Hoechst AG vormals Meister Lucius & Brüning, 6000 Frankfurt Neue Azetidinone-(2) und Verfahren zu deren Herstellung
CA1063108A (en) 1973-12-28 1979-09-25 Fujisawa, Pharmaceutical Co. Azetidinone derivatives and process for preparation thereof
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4144232A (en) 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
IL65158A0 (en) 1981-03-09 1982-05-31 Lilly Co Eli Azetidinones
US4500456A (en) 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4784734A (en) 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4443372A (en) 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
GR81665B (de) 1983-02-02 1984-12-12 Univ Notre Dame Du Lac
US4595532A (en) 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
US4565654A (en) 1983-03-28 1986-01-21 University Of Notre Dame Du Lac N-Acyloxy monocyclic β-lactams
US4675399A (en) 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
WO1985004876A1 (fr) 1984-04-24 1985-11-07 Takeda Chemical Industries, Ltd. Derives de 2-azetidinone et leur procede de preparation
US4576749A (en) 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US4680391A (en) 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229381A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229510A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
JPS61501205A (ja) 1984-02-15 1986-06-19 シェリング・コ−ポレ−ション ８↓−クロル↓−６，１１↓−ジヒドロ↓−１１↓−（４↓−ピペリジリデン）↓−５Ｈ↓−ベンゾ〔５，６〕シクロヘプタ〔１，２−ｂ〕ピリジンおよびその塩、これらの化合物の製造方法、ならびにこれらの化合物を含有する医薬組成物
US4581170A (en) 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
CA1268780A (en) 1984-08-03 1990-05-08 Richard H. Mueller N-hydroxyl protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4633017A (en) 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4620867A (en) 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
JPH01501470A (ja) 1986-01-23 1989-05-25 ジ・アップジョン・カンパニ− 抗菌性ｎ−アシル−２−アゼチジノン
US4847271A (en) 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
USRE36481E (en) 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
US4806564A (en) 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US4816477A (en) 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
US4834846A (en) 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
EP0333268A1 (de) 1988-03-18 1989-09-20 Merck & Co. Inc. Verfahren zur Synthese eines chiralen 3-beta-Wasserstoff-(3R) 4-aroyloxyazetidinons
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
JPH0645656B2 (ja) 1988-06-16 1994-06-15 出光石油化学株式会社 スチレン系共重合体およびその製造方法
US4952689A (en) 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
US4876365A (en) 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
FR2640621B1 (fr) 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
CA2016467A1 (en) 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
JPH03108490A (ja) * 1989-06-30 1991-05-08 Shionogi & Co Ltd フォスフォリパーゼａ↓２阻害物質
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
IL99658A0 (en) 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1992018462A1 (en) 1991-04-12 1992-10-29 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
US5124337A (en) 1991-05-20 1992-06-23 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
GB2264707A (en) 1991-06-18 1993-09-08 Roger Michael Marchbanks Acridine derivatives for treating alzheimer's disease
WO1993000332A1 (en) 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5348953A (en) 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
DE69222532T2 (de) * 1991-07-23 1998-02-26 Schering Corp Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung
CA2114007C (en) 1991-07-23 2005-12-20 Duane A. Burnett Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
JP2620437B2 (ja) * 1991-09-27 1997-06-11 宇部興産株式会社 ω−ヒドロキシ−（ω−３）−ケトニトリルおよびω−ヒドロキシ脂肪酸の製法
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
US5321031A (en) 1992-09-23 1994-06-14 Schering Corporation 1,2-disubstituted ethyl amides as inhibitors of ACAT
US5631363A (en) 1992-11-13 1997-05-20 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
WO1994017036A1 (en) 1993-01-22 1994-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) S-lipophilic aliphatic carbonyl [n-mercaptoacyl-(amino acid or peptide)] compounds as antihypertensive agents
EP0686157A1 (de) 1993-02-26 1995-12-13 Schering Corporation 2-benzylpolycyclisch guaninderivate und verfahren zu ihrer herstellung
US5412092A (en) 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
EP0707567B1 (de) 1993-07-09 2001-09-12 Schering Corporation Verfahren zur herstellung von azetidinonen
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
GB9406074D0 (en) 1994-03-26 1994-05-18 Glaxo Spa Chemical process
US5576470A (en) 1994-08-29 1996-11-19 Henkel Corporation Polyol esters of ether carboxylic acids and fiber finishing methods
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
AU7472896A (en) 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
EP0855396A1 (de) 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Metabolite von Thioctsäure und deren Verwendung
WO1999042105A1 (en) 1998-02-20 1999-08-26 Avmax, Inc. Epimorphian compound and its use
US6465490B1 (en) 1999-07-16 2002-10-15 Aventis Pharmaceuticals Inc. Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
NZ518822A (en) 1999-11-04 2004-12-24 Andrx Corp Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor
EP1268453B1 (de) 2000-04-07 2006-07-19 Pfizer Products Inc. Metabolite von estrogen-agonisten/-antagonisten
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
CA2172149C (en) 2000-11-28
PL313589A1 (en) 1996-07-08
TNSN94094A1 (fr) 1995-04-25
FR14C0068I1 (fr) 2014-10-17
NL300132I1 (nl) 2003-10-01
EP0720599A1 (de) 1996-07-10
BR1100159A (pt) 2006-09-26
FI961300A7 (fi) 1996-03-21
MY111314A (en) 1999-10-30
NO2014023I1 (no) 2014-09-12
NO2017042I1 (no) 2017-08-02
IL110956A0 (en) 1994-11-28
CN1050830C (zh) 2000-03-29
NL300132I2 (nl) 2003-11-03
ATE180249T1 (de) 1999-06-15
NL300172I2 (nl) 2005-08-01
JPH08509989A (ja) 1996-10-22
DE69418613T2 (de) 1999-09-30
AU681445B2 (en) 1997-08-28
NO305902B1 (no) 1999-08-16
DE122004000026I1 (de) 2004-11-18
FI110321B (fi) 2002-12-31
AU681445C (en) 2004-07-08
USRE42461E1 (en) 2011-06-14
RU2138480C1 (ru) 1999-09-27
AU7795294A (en) 1995-04-10
HU9600697D0 (en) 1996-05-28
SK35596A3 (en) 1997-02-05
MA23332A1 (fr) 1995-04-01
NZ274041A (en) 1997-12-19
NO2003007I2 (no) 2005-08-29
SK281067B6 (sk) 2000-11-07
DE69418613D1 (de) 1999-06-24
CZ83996A3 (en) 1996-08-14
LU91050I2 (fr) 2004-10-12
NO2005003I2 (no) 2005-10-03
KR960704842A (ko) 1996-10-09
USRE37721E1 (en) 2002-05-28
FR05C0040I1 (de) 2005-10-28
LU91160I2 (fr) 2005-11-25
DE122004000026I2 (de) 2005-09-29
JP2803908B2 (ja) 1998-09-24
UA41948C2 (uk) 2001-10-15
PL182617B1 (pl) 2002-02-28
GEP20043149B (en) 2004-01-12
NO2005003I1 (no) 2005-02-28
ZA947086B (en) 1995-03-14
EP0720599B1 (de) 1999-05-19
ES2132432T3 (es) 1999-08-16
HUT73852A (en) 1996-09-30
IL110956A (en) 2001-01-11
CN1131416A (zh) 1996-09-18
GR3030312T3 (en) 1999-09-30
NO961133D0 (no) 1996-03-20
LU92544I2 (fr) 2015-01-20
US5631365A (en) 1997-05-20
NL300172I1 (nl) 2005-04-01
KR100186853B1 (ko) 1999-05-01
LU92545I2 (fr) 2015-09-21
SG46208A1 (en) 1998-02-20
FI961300A0 (fi) 1996-03-21
DE10399001I1 (de) 2003-06-12
CZ288861B6 (cs) 2001-09-12
US5767115A (en) 1998-06-16
TW427974B (en) 2001-04-01
NO961133L (no) 1996-03-20
DE10399001I2 (de) 2012-05-16
FR05C0040I2 (fr) 2006-12-29
WO1995008532A1 (en) 1995-03-30
US5846966A (en) 1998-12-08
CZ288891B6 (cs) 2001-09-12
BE2014C056I2 (en) 2018-02-05
NO2014022I1 (no) 2014-09-10
HU221185B1 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
DK0720599T3 (da) Som hypocholesterolæmiske midler anvendelige hydroxysubstituerede azetidinoner
TW568896B (en) Calcium receptor-active compounds
MX9202993A (es) Derivados de naftoquinonas.
FI961507A0 (fi) Antrasyklinonijohdannaiset ja niiden käyttö amyloidoosissa
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
FI923050A0 (fi) Nya benzomorfaner och deras anvaendning som laekemedel.
NO179865C (no) Nytt -fenylisoserinderivat og dets fremstilling
BR9801448B1 (pt) compostos heterocÍclicos, processo para sua preparaÇço e composiÇÕes farmacÊuticas contendo os mesmos.
ES450399A1 (es) Un procedimiento para la preparacion de un derivado de ce- fem.